DaShenLin Pharmaceutical Group Co., Ltd. announced a private placement of not more than 284,735,538 A Shares for gross proceeds of not more than CNY 3,025,000,000 on January 19, 2023. The transaction will include participation from no more than 35 specific investors. The issue price shall not be lower than 80% of the average stock trading price in the 20 trading days prior to the pricing base date.

The number of shares to be issued shall not exceed 30% of the company's total share capital before this offering. The transaction has been deliberated and approved at the 34th meeting of the third board of directors of the company, and still need to be deliberated and approved by the company's general meeting of shareholders and approved by the China Securities Regulatory Commission. The securities to be issued in the transaction will be subject to a 6 month hold period from date of completion of the issuance.

The resolution for the transaction is valid for 12 months from the date when the issuance plan is reviewed and approved by the general meeting of shareholders.